J Clin Oncol: Donor-derived CD7 chimeric antigen receptor T cells for the treatment of acute T lymphocytic leukemia can be expected in the future!

Acute T-lymphocytic leukemia (T-ALL) is an aggressive hematological malignancy that accounts for 10%-15% of childhood acute lymphoblastic leukemia (ALL) cases and 20% of adult ALL cases
.

Patients with relapsed or refractory T-ALL (r/r T-ALL) have few treatment options and poor prognosis

child

The purpose of this study is to evaluate the efficacy and safety of patient-derived anti-CD7 chimeric antigen receptor (CAR) T cells used in r/r T-ALL patients
.

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial

This is a single-center phase 1 trial in which CD7 CAR T cells were infused into r/r T-ALL patients at a dose of 5×10 ⁵ /kg or 1×10 ⁶ /kg (±30%)
.

The primary endpoint is safety, and the secondary endpoint is efficacy

^{5 6}

A total of 20 patients received CAR T cell infusion
.

Adverse events include cytokine release syndrome (grade 1-2: 90%; grade 3-4: 10%), grade 3-4 cytopenia (100%), grade 1-2 neurotoxicity (15%) ), grade 1-2 graft versus host disease (60%), and grade 1-2 virus activation (20%)

Adverse events include cytokine release syndrome (grade 1-2: 90%; grade 3-4: 10%), grade 3-4 cytopenia (100%), grade 1-2 neurotoxicity (15%) ), grade 1-2 graft versus host disease (60%), and grade 1-2 virus activation (20%)

Clinical remission

Clinical remission

Ninety percent of patients achieved complete remission, and 7 patients underwent stem cell transplantation
.

At a median follow-up of 6.

Ninety percent of patients achieved complete remission, and 7 patients underwent stem cell transplantation

immunity

In summary, among the 20 r/r T-ALL patients who participated in the trial, the donor-derived CD7 CAR T cells showed effective expansion, and achieved a high complete remission rate and controllable safety.
Sex
.

Donor-derived CD7 CAR T cells showed effective expansion and achieved a high complete remission rate and controllable safety
.

Donor-derived CD7 CAR T cells showed effective expansion and achieved a high complete remission rate and controllable safety

Original source:

Jing Pan, et al.

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial in this message